In diabetic women with polycystic ovarian syndromes (PCOs), a condition characterized by anovulatory androgen secretion, relatively high E2, and excessive LH production [23–25], treatment with the PPARγ agonists rosiglitazone or pioglitazone improved insulin resistance and decreased hyperandrogenism in multiple studies (reviewed in [26–28]). Here, PLOD1 is linked to polycystic ovary syndrome.